JP7830029B2 - 制御可能なイントロンを用いる発現調節 - Google Patents

制御可能なイントロンを用いる発現調節

Info

Publication number
JP7830029B2
JP7830029B2 JP2020531824A JP2020531824A JP7830029B2 JP 7830029 B2 JP7830029 B2 JP 7830029B2 JP 2020531824 A JP2020531824 A JP 2020531824A JP 2020531824 A JP2020531824 A JP 2020531824A JP 7830029 B2 JP7830029 B2 JP 7830029B2
Authority
JP
Japan
Prior art keywords
sequence
expression
intron
nucleic acid
cng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020531824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533019A (ja
JP2020533019A5 (enExample
Inventor
グラハム・ホワイトサイド
Original Assignee
アスクバイオ・ユーケー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスクバイオ・ユーケー・リミテッド filed Critical アスクバイオ・ユーケー・リミテッド
Publication of JP2020533019A publication Critical patent/JP2020533019A/ja
Publication of JP2020533019A5 publication Critical patent/JP2020533019A5/ja
Priority to JP2023111541A priority Critical patent/JP2023118937A/ja
Application granted granted Critical
Publication of JP7830029B2 publication Critical patent/JP7830029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020531824A 2017-08-23 2018-08-22 制御可能なイントロンを用いる発現調節 Active JP7830029B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023111541A JP2023118937A (ja) 2017-08-23 2023-07-06 制御可能なイントロンを用いる発現調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1713545.0 2017-08-23
GBGB1713545.0A GB201713545D0 (en) 2017-08-23 2017-08-23 Expression control using a regulatable intron
PCT/GB2018/052387 WO2019038544A1 (en) 2017-08-23 2018-08-22 EXPRESSION CONTROL USING AN ADJUSTABLE INTRON

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023111541A Division JP2023118937A (ja) 2017-08-23 2023-07-06 制御可能なイントロンを用いる発現調節

Publications (3)

Publication Number Publication Date
JP2020533019A JP2020533019A (ja) 2020-11-19
JP2020533019A5 JP2020533019A5 (enExample) 2021-09-24
JP7830029B2 true JP7830029B2 (ja) 2026-03-16

Family

ID=59996625

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020531824A Active JP7830029B2 (ja) 2017-08-23 2018-08-22 制御可能なイントロンを用いる発現調節
JP2023111541A Pending JP2023118937A (ja) 2017-08-23 2023-07-06 制御可能なイントロンを用いる発現調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023111541A Pending JP2023118937A (ja) 2017-08-23 2023-07-06 制御可能なイントロンを用いる発現調節

Country Status (8)

Country Link
US (2) US11492618B2 (enExample)
EP (1) EP3673068A1 (enExample)
JP (2) JP7830029B2 (enExample)
CN (2) CN111566216B (enExample)
AU (2) AU2018319637B2 (enExample)
GB (1) GB201713545D0 (enExample)
IL (2) IL314845A (enExample)
WO (1) WO2019038544A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3171636A1 (en) * 2020-03-26 2021-09-30 Graham WHYTESIDE Forskolin-inducible promoters and hypoxia-inducible promoters
US20230407327A1 (en) * 2020-03-26 2023-12-21 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production
WO2021209743A1 (en) * 2020-04-15 2021-10-21 Synpromics Limited Forskolin-inducible promoters and hypoxia-inducible promoters
JP7898267B2 (ja) * 2021-10-20 2026-07-31 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
WO2025024776A2 (en) * 2023-07-27 2025-01-30 Duke University Compositions comprising xbp1 fragments and methods of use in gene therapy
WO2026015884A1 (en) * 2024-07-11 2026-01-15 Helix Nanotechnologies Inc Compositions comprising ire-1 binding sequences and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP4446057B2 (ja) * 2002-08-28 2010-04-07 独立行政法人理化学研究所 生体刺激存在下でのｍＲＮＡのフレームシフトを利用した蛋白質の発現方法
AU2003268356A1 (en) * 2002-08-30 2004-03-19 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
US20070111258A1 (en) * 2005-06-22 2007-05-17 Kaufman Randal J Compositions and methods for modulating the acute phase response
US8227184B2 (en) * 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
WO2010151827A1 (en) * 2009-06-25 2010-12-29 Bayer Healthcare Llc X-box binding proteins (xbp-1) variants and methods of using the same
US20200393447A1 (en) * 2017-07-09 2020-12-17 Thomas Hughes Biosensors for measuring cell signaling in stressed and healthy cells
WO2021195491A2 (en) * 2020-03-26 2021-09-30 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EMBO reports, 2015年, Vol. 16, No. 12, p. 1688-1698
Journal of Biological Chemistry, 2006年, Vol.281(27), p.18691-18706
PLOS ONE, 2017年7月23日, Vol.12(8), e0183694
pLPCX - Addgene Vector Database (Plasmids, Expression Vectors, etc), [online], 2012年12月20日保存, [2022年6月14日検索], インターネット＜https://web.archive.org/web/20121220043132/https://www.addgene.org/vector-database/3473/＞

Also Published As

Publication number Publication date
EP3673068A1 (en) 2020-07-01
JP2023118937A (ja) 2023-08-25
US11492618B2 (en) 2022-11-08
AU2018319637A1 (en) 2020-03-12
JP2020533019A (ja) 2020-11-19
US20200199593A1 (en) 2020-06-25
IL314845A (en) 2024-10-01
CA3073366A1 (en) 2019-02-28
IL272800B1 (en) 2024-09-01
NZ761945A (en) 2024-09-27
GB201713545D0 (en) 2017-10-04
CN111566216B (zh) 2024-07-02
IL272800B2 (en) 2025-01-01
WO2019038544A1 (en) 2019-02-28
AU2025205352A1 (en) 2025-07-31
IL272800A (en) 2020-04-30
US12600969B2 (en) 2026-04-14
AU2018319637B2 (en) 2025-04-10
CN118562839A (zh) 2024-08-30
CN111566216A (zh) 2020-08-21
US20230304003A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US12600969B2 (en) Expression control using a regulatable intron
EP1939291B1 (fr) Oligonucléotides inhibiteurs et leur utilisation pour réprimer spécifiquement un gène
US8470797B2 (en) Inducible small RNA expression constructs for targeted gene silencing
EP2166107A1 (en) Lentiviral vectors for the expression of shRNA
JP2006505288A (ja) 対立遺伝子特異的ｒｎａ干渉
EP3430143B1 (en) Inhibitors of srsf1 to treat neurodegenerative disorders
US12472269B2 (en) Liver-specific inducible promoters and methods of use thereof
Bhakta et al. Double MS2 guided restoration of genetic code in amber (TAG), opal (TGA) and ochre (TAA) stop codon
Yuan et al. Suppression of keratoepithelin and myocilin by small interfering RNAs (siRNA) in vitro
US20230374526A1 (en) Forskolin-inducible promoters and hypoxia-inducible promoters
JP2023517581A (ja) ＣＰＲ富化メタゲノム由来のＣＲＩＳＰＲ－Ｃａｓヌクレアーゼ
CA3073366C (en) Expression control using a regulatable intron
HK40114268A (en) Expression control using a regulatable intron
Peng et al. shRNA driven by Pol II/T7 dual-promoter system effectively induce cell-specific RNA interference in mammalian cells
US12365900B2 (en) miRNA switches for RNA-triggered control of RNA interference
Shao et al. The reversion effect of the RNAi-silencing mdr1 gene on multidrug resistance of the leukemia cell HT9
Huang SUPPRESSION OF KERATOEPITHELIN AND MYOCILIN BY SMALL INTERFERING RNA (AN AMERICAN OPTHALMOLOGICAL SOCIETY THESIS)
WO2003070932A1 (en) Polynucleotide for target gene
US20060189560A1 (en) Molecular method to augment RNA mediated gene silencing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230718

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260304

R150 Certificate of patent or registration of utility model

Ref document number: 7830029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150